一例替格瑞洛诱发的窦性停搏病例。

Pavlatos Nicholas T, Shah Aangi, Khan Muhammad, Jaiswal Vikash, Mattumpuram Jishanth

Department of Internal Medicine, University of Louisville Hospital, Louisville, USA.

Department of Cardiology, University of Louisville Hospital, Louisville, USA.

Cureus. 2023 Jul 13;15(7):e41821. doi: 10.7759/cureus.41821. eCollection 2023 Jul.

Ticagrelor is an oral antiplatelet agent commonly used following percutaneous coronary intervention (PCI). There have been many reports describing bradyarrhythmias in the setting of ticagrelor use, most notably sinus pauses. This process is thought to be related to ticagrelor's inhibition of human equilibrative nucleoside transporter (hENT1), which reduces cellular uptake of adenosine. We present a case of a 58-year-old male who experienced prolonged sinus pauses 38 hours after starting ticagrelor following ST-elevation myocardial infarction with subsequent PCI and stent placement.

替格瑞洛是一种常用于经皮冠状动脉介入治疗（PCI）后的口服抗血小板药物。有许多报告描述了使用替格瑞洛时出现的缓慢性心律失常，最显著的是窦性停搏。这个过程被认为与替格瑞洛抑制人平衡核苷转运体（hENT1）有关，hENT1的抑制会减少细胞对腺苷的摄取。我们报告一例58岁男性患者，在ST段抬高型心肌梗死后接受PCI及支架置入术并开始使用替格瑞洛38小时后出现了长时间的窦性停搏。